The Claim
Inclisiran, a small interfering RNA therapeutic, reduces hepatic production of PCSK9 within hepatocytes by targeting its mRNA, resulting in decreased intracellular and extracellular PCSK9 protein levels, which leads to an approximately 50% reduction in plasma LDL-cholesterol levels, offering a longer-acting alternative to monoclonal antibody therapies targeting PCSK9.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Inclisiran is a type of medicine that helps lower bad cholesterol by turning down a protein in the liver. It works longer than some other cholesterol drugs, so you don’t need to take it as often.
See the scientific wording
Inclisiran, a small interfering RNA, reduces hepatic production of PCSK9 inside hepatocytes, leading to approximately 50% reduction in plasma LDL-cholesterol levels by decreasing both intracellular and extracellular PCSK9 protein, offering a longer-acting alternative to monoclonal antibodies.
What the research says
1 studyStudy: Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?
The study shows that inclisiran works by reducing the production of a protein called PCSK9 in the liver, which lowers bad cholesterol by about half, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.